Amylin Halts Development Of Symlin With Approved Appetite Suppressants
This article was originally published in The Pink Sheet Daily
Executive Summary
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.